Applications of artemisinin compounds in preparing medicines for treating liposarcoma

Abstract

The invention relates to the field of medicines, and in particular relates to applications of artemisinin compounds in preparing medicines for treating liposarcoma. The artemisinin compounds are shownin the description. The experiment proves that the compounds can obviously prolong the progression free survival (PFS) of patients and improve the life quality of the patients, while the number of circulating tumor cells (CTCs) is obviously reduced, the ratios of T cell subsets in the peripheral blood are obviously improved, in addition, the safety is high, and the applications are disclosed forthe first time and have the outstanding substantive features. The substances can be applied to preparation of medicines for treating liposarcoma and have good market application prospects.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of an artemisinin compound in the preparation of a drug for treating liposarcoma. Background technique [0002] Liposarcoma (liposarcomas) is a common malignant soft tissue tumor, which originates from mesenchymal cells differentiated from lipoblasts to adipocytes. According to different cell components, liposarcoma can be divided into: ① Well-differentiated liposarcoma, also known as fat Tumor-like liposarcoma; ②myxoid liposarcoma; ③round cell liposarcoma; ④pleomorphic liposarcoma; The disease is more common in patients aged 30 to 70, and the most common disease is around the age of 50. Men outnumber women. Extremities, especially thighs and buttocks are prone to occur. Upper limbs, retroperitoneum, head, and neck masses are more common with a diameter of 3 to 10 cm, and those with a large retroperitoneum can reach a diameter of more than 20 cm. The tumor is often nodul...

AI Technical Summary

Problems solved by technology

[0003] At present, the treatment of liposarcoma is mainly based on surgical treatment, radiotherapy and auxiliary drug treatment, but surgical treatment not only causes great trauma to the patient's body, but also causes inconvenience to the patient's life, easily causes complications, and the treatment cost is high

In recent years, international pharmaceutical companies have invested heavily in the development of anti-liposarcoma drugs, and some new drugs and new treatments have been applied to clinical treatment. In 2015, the FDA approved Lartruvo developed by Eli Lilly and Company. TM Combined with doxorubicin for the treatment of soft tissue sarcoma, in January 2016, the FDA approved Halaven (eribulin mesylate) developed by the Japanese pharmaceutical company Eisai for the treatment of advanced or metastatic liposarcoma. However, the high cost of treatment and the tolerance challenges brought about by cytotoxic chemotherapy drugs have brought great pressure on the patient's economy and body. Therefore, the development of a drug with relatively less toxic side effects, Anti-liposarcoma drugs with definite curative effect and relatively broad spectrum, which are affordable by ordinary people, have become an urgent need

So far, there have been no relevant reports on artemisinin compounds against liposarcoma

Images